Telavancin: A Review of its Use in Treating Gram-Positive Infections
暂无分享,去创建一个
[1] J. Janc,et al. Effects of telavancin on coagulation test results , 2011, International journal of clinical practice.
[2] R. Danesi,et al. Case Report of a Successful Treatment of Methicillin-Resistant Staphylococcus aureus (MRSA) Bacteremia and MRSA/Vancomycin-Resistant Enterococcus faecium Cholecystitis by Daptomycin , 2011, Antimicrobial Agents and Chemotherapy.
[3] M. Niederman,et al. Telavancin versus Vancomycin for Hospital-Acquired Pneumonia due to Gram-positive Pathogens , 2011, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[4] D. Paterson,et al. Systematic Review and Meta-Analysis of the Significance of Heterogeneous Vancomycin-Intermediate Staphylococcus aureus Isolates , 2010, Antimicrobial Agents and Chemotherapy.
[5] K. Krause,et al. In vitro activity of telavancin against Gram-positive isolates from complicated skin and skin structure infections: results from 2 phase 3 (ATLAS) clinical studies. , 2010, Diagnostic microbiology and infectious disease.
[6] B. Camins,et al. Successful Treatment of Vancomycin-Intermediate Staphylococcus aureus Pacemaker Lead Infective Endocarditis with Telavancin , 2010, Antimicrobial Agents and Chemotherapy.
[7] J. Shaw,et al. Single‐Dose Pharmacokinetics and Tolerability of Telavancin in Elderly Men and Women , 2010, Pharmacotherapy.
[8] R. Seaton,et al. Outpatient parenteral antimicrobial therapy: Recent developments and future prospects. , 2010, Current opinion in investigational drugs.
[9] Ronald N. Jones,et al. Telavancin activity against Gram-positive bacteria isolated from respiratory tract specimens of patients with nosocomial pneumonia. , 2010, The Journal of antimicrobial chemotherapy.
[10] Stephanie R Hartouni,et al. Fluorescence Microscopy Demonstrates Enhanced Targeting of Telavancin to the Division Septum of Staphylococcus aureus , 2010, Antimicrobial Agents and Chemotherapy.
[11] S. Barriere,et al. Effect of Telavancin on the Pharmacokinetics of the Cytochrome P450 3A Probe Substrate Midazolam: A Randomized, Double‐Blind, Crossover Study in Healthy Subjects , 2010, Pharmacotherapy.
[12] J. Shaw,et al. Lack of Effect of Moderate Hepatic Impairment on the Pharmacokinetics of Telavancin , 2010, Pharmacotherapy.
[13] G. Stein,et al. Telavancin: a novel lipoglycopeptide. , 2009, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[14] S. Finegold,et al. In Vitro Activities of Telavancin and Six Comparator Agents against Anaerobic Bacterial Isolates , 2009, Antimicrobial Agents and Chemotherapy.
[15] M. Kinzig,et al. Lack of Pharmacokinetic Drug Interactions Following Concomitant Administration of Telavancin with Aztreonam or Piperacillin/Tazobactam in Healthy Participants , 2009, Journal of clinical pharmacology.
[16] S. Wilson,et al. Telavancin versus vancomycin for the treatment of complicated skin and skin-structure infections associated with surgical procedures. , 2009, American journal of surgery.
[17] M. Mammen,et al. Telavancin Disrupts the Functional Integrity of the Bacterial Membrane through Targeted Interaction with the Cell Wall Precursor Lipid II , 2009, Antimicrobial Agents and Chemotherapy.
[18] L. Mermel,et al. In Vitro Activities of Telavancin and Vancomycin against Biofilm-Producing Staphylococcus aureus, S. epidermidis, and Enterococcus faecalis Strains , 2009, Antimicrobial Agents and Chemotherapy.
[19] J. Calhoun,et al. Efficacy of telavancin in the treatment of methicillin-resistant Staphylococcus aureus osteomyelitis: studies with a rabbit model. , 2008, The Journal of antimicrobial chemotherapy.
[20] P. Appelbaum,et al. Postantibiotic Effects of Telavancin against 16 Gram-Positive Organisms , 2008, Antimicrobial Agents and Chemotherapy.
[21] M. Goldberg,et al. Multiple-dose pharmacokinetics of intravenous telavancin in healthy male and female subjects. , 2008, The Journal of antimicrobial chemotherapy.
[22] K. Krause,et al. In vitro activity of telavancin against recent Gram-positive clinical isolates: results of the 2004-05 Prospective European Surveillance Initiative. , 2008, The Journal of antimicrobial chemotherapy.
[23] R. Moellering,et al. Increasing antibiotic resistance among methicillin-resistant Staphylococcus aureus strains. , 2008, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[24] V. Fowler,et al. Telavancin versus vancomycin for the treatment of complicated skin and skin-structure infections caused by gram-positive organisms. , 2008, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[25] K. Krause,et al. Comparative Surveillance Study of Telavancin Activity against Recently Collected Gram-Positive Clinical Isolates from across the United States , 2008, Antimicrobial Agents and Chemotherapy.
[26] K. Krause,et al. In Vitro Activity of Telavancin against Resistant Gram-Positive Bacteria , 2008, Antimicrobial Agents and Chemotherapy.
[27] J. Shaw,et al. Intrapulmonary Distribution of Intravenous Telavancin in Healthy Subjects and Effect of Pulmonary Surfactant on In Vitro Activities of Telavancin and Other Antibiotics , 2007, Antimicrobial Agents and Chemotherapy.
[28] L. Friedrich,et al. Vancomycin MIC creep in non-vancomycin-intermediate Staphylococcus aureus (VISA), vancomycin-susceptible clinical methicillin-resistant S. aureus (MRSA) blood isolates from 2001-05. , 2007, The Journal of antimicrobial chemotherapy.
[29] L. Saravolatz,et al. Comparative activity of telavancin against isolates of community-associated methicillin-resistant Staphylococcus aureus. , 2007, The Journal of antimicrobial chemotherapy.
[30] V. Fowler,et al. Telavancin versus Standard Therapy for Treatment of Complicated Skin and Skin Structure Infections Caused by Gram-Positive Bacteria: FAST 2 Study , 2006, Antimicrobial Agents and Chemotherapy.
[31] J. Shaw,et al. Tissue Penetration of Telavancin after Intravenous Administration in Healthy Subjects , 2006, Antimicrobial Agents and Chemotherapy.
[32] A. Stucki,et al. Efficacy of Telavancin against Penicillin-Resistant Pneumococci and Staphylococcus aureus in a Rabbit Meningitis Model and Determination of Kinetic Parameters , 2006, Antimicrobial Agents and Chemotherapy.
[33] H. Chambers,et al. Efficacy of Telavancin in a Rabbit Model of Aortic Valve Endocarditis Due to Methicillin-Resistant Staphylococcus aureus or Vancomycin-Intermediate Staphylococcus aureus , 2005, Antimicrobial Agents and Chemotherapy.
[34] V. Fowler,et al. Telavancin versus standard therapy for treatment of complicated skin and soft-tissue infections due to gram-positive bacteria. , 2005, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[35] D. Snydman,et al. Daptomycin-resistant, methicillin-resistant Staphylococcus aureus bacteremia. , 2005, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[36] Deborah L. Higgins,et al. Telavancin, a Multifunctional Lipoglycopeptide, Disrupts both Cell Wall Synthesis and Cell Membrane Integrity in Methicillin-Resistant Staphylococcus aureus , 2005, Antimicrobial Agents and Chemotherapy.
[37] Deborah L. Higgins,et al. Pharmacokinetics, Serum Inhibitory and Bactericidal Activity, and Safety of Telavancin in Healthy Subjects , 2005, Antimicrobial Agents and Chemotherapy.
[38] E. Goldstein,et al. In Vitro Activities of the New Semisynthetic Glycopeptide Telavancin (TD-6424), Vancomycin, Daptomycin, Linezolid, and Four Comparator Agents against Anaerobic Gram-Positive Species and Corynebacterium spp , 2004, Antimicrobial Agents and Chemotherapy.
[39] M. Kaufmann,et al. Linezolid-resistant enterococci: report of the first isolates in the United Kingdom. , 2002, The Journal of antimicrobial chemotherapy.